基于疾病图谱的膀胱癌诊断生物标志物选择与预验证
Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.
作者信息
De Paoli Marine, Perco Paul, Mühlberger Irmgard, Lukas Arno, Pandha Hardev, Morgan Richard, Feng Gui Jie, Marquette Christophe
机构信息
a AXO Science SAS , Lyon , France .
出版信息
Biomarkers. 2015;20(5):328-37. doi: 10.3109/1354750X.2015.1068867. Epub 2015 Jul 31.
CONTEXT
Urinary biomarkers are promising as simple alternatives to cystoscopy for the diagnosis of de novo and recurrent bladder cancer.
OBJECTIVE
To identify a highly sensitive and specific biomarker candidate set with potential clinical utility in bladder cancer.
MATERIALS AND METHODS
Urinary biomarker concentrations were determined by ELISA. The performance of individual markers and marker combinations was assessed using ROC analysis.
RESULTS
A five-biomarker panel (IL8, MMP9, VEGFA, PTGS2 and EN2) was defined from the candidate set.
DISCUSSION AND CONCLUSION
This panel showed a better overall performance than the best individual marker. Further validation studies are needed to evaluate its clinical utility in bladder cancer.
背景
尿液生物标志物有望成为膀胱镜检查的简单替代方法，用于诊断原发性和复发性膀胱癌。
目的
确定一组在膀胱癌中具有潜在临床应用价值的高敏感性和特异性生物标志物候选物。
材料与方法
通过酶联免疫吸附测定法（ELISA）测定尿液生物标志物浓度。使用ROC分析评估单个标志物和标志物组合的性能。
结果
从候选物中确定了一个由五种生物标志物组成的组合（IL8、MMP9、VEGFA、PTGS2和EN2）。
讨论与结论
该组合的整体性能优于最佳单个标志物。需要进一步的验证研究来评估其在膀胱癌中的临床应用价值。
Zotero 插件